Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis

A Phase 1b/2a clinical trial of NDV-3A vaccine containing a Candida albicans recombinant Als3 protein formulated with alum protected women <40 years old from recurrent vulvovaginal candidiasis (RVVC). We investigated the potential use of anti-Als3p sera as surrogate marker of NDV-3A efficacy. Pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Uppuluri, Priya, Singh, Shakti, Alqarihi, Abdullah, Schmidt, Clint S., Hennessey, John P., Yeaman, Michael R., Filler, Scott G., Edwards, John E., Ibrahim, Ashraf S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013566/
https://www.ncbi.nlm.nih.gov/pubmed/29963049
http://dx.doi.org/10.3389/fimmu.2018.01349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013566/
https://www.ncbi.nlm.nih.gov/pubmed/29963049
http://dx.doi.org/10.3389/fimmu.2018.01349

Ejemplares similares